IKT (Inhibikase Therapeutics) Moat Score: 2/10 (As of Jul. 03, 2026)


IKT Inhibikase Therapeutics Inc IKT
28 GF Score
Price $1.99
! 1 Warning Sign
View Full Analysis

What is Inhibikase Therapeutics Moat Score?

Inhibikase Therapeutics IKT +3.11% 28 Moat Score is 2 as of Jul. 03, 2026. GuruFocus rates IKT with a GF Score™ of 28/100. The stock has 1 warning sign investors should review. Among 1,399 Biotechnology companies, Inhibikase Therapeutics ranks better than 58.11% on this metric.

Inhibikase Therapeutics has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

Inhibikase Therapeutics has No Moat: Inhibikase Therapeutics Inc lacks market leadership and significant intellectual property. The company does not have strong brand strength, customer loyalty, or regulatory barriers, resulting in a very weak competitive position.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Inhibikase Therapeutics might have No Moat - Very weak/transient advantages.

Inhibikase Therapeutics  (NAS:IKT) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Inhibikase Therapeutics Moat Score Related Terms

IKT vs FHTX, OBIO, FULC: Moat Score Comparison

For the Biotechnology subindustry, Inhibikase Therapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Inhibikase Therapeutics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inhibikase Therapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where Inhibikase Therapeutics's Moat Score falls into.


IKT
28GF Score
Inhibikase Therapeutics Inc IKT
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
Inhibikase Therapeutics (IKT) has a Moat Score of 2 as of Jul. 03, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Inhibikase Therapeutics ranks #586 out of 1399 companies in the Biotechnology industry, placing it in the top 41.9%.
Is Inhibikase Therapeutics' Moat Score too high?
Inhibikase Therapeutics' current Moat Score is 2. The Biotechnology industry median Moat Score is 2.00. Inhibikase Therapeutics' value of 2 is 0% at this industry median. Based on the distribution chart, Inhibikase Therapeutics ranks #586 out of 1399 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Inhibikase Therapeutics has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Inhibikase Therapeutics' Moat Score compare to FHTX and OBIO?
According to the Biotechnology industry distribution chart, Inhibikase Therapeutics ranks #586 out of 1399 companies for Moat Score. This puts Inhibikase Therapeutics in the upper half of its industry. The industry median Moat Score is 2.00. Inhibikase Therapeutics' value of 2 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,399 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Inhibikase Therapeutics's current Moat Score of 2 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Inhibikase Therapeutics's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inhibikase Therapeutics stock overvalued right now?
Inhibikase Therapeutics (IKT) has a current Moat Score of 2. The current Moat Score is 2 and 0% at the Biotechnology industry median of 2.00. Inhibikase Therapeutics' overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Inhibikase Therapeutics (IKT), the current Moat Score is 2 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Inhibikase Therapeutics Business Description

Address 1000 N. West Street, Suite 1200, Wilmington, DE, USA, 19801
Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.
28GF Score

Get the complete analysis for IKT

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.99
Price